LENZ Therapeutics, Inc. (LENZ)
NASDAQ: LENZ · Real-Time Price · USD
7.20
+0.55 (8.27%)
At close: May 20, 2026, 4:00 PM EDT
7.09
-0.11 (-1.53%)
After-hours: May 20, 2026, 4:47 PM EDT
LENZ Therapeutics Revenue
LENZ Therapeutics had revenue of $1.90M in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $20.99M. In the year 2025, LENZ Therapeutics had annual revenue of $19.09M.
Revenue (ttm)
$20.99M
Revenue Growth
n/a
P/S Ratio
10.04
Revenue / Employee
$138,086
Employees
152
Market Cap
225.75M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 19.09M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 15.00M | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Voyager Therapeutics | 36.49M |
| Foghorn Therapeutics | 28.22M |
| Sol-Gel Technologies | 19.39M |
| MediWound | 16.96M |
| Whitehawk Therapeutics | 7.15M |
| Entrada Therapeutics | 5.74M |
| Camp4 Therapeutics | 3.93M |
LENZ News
- 7 days ago - Lenz Therapeutics price target lowered to $20 from $26 at Citi - TheFly
- 8 days ago - LENZ Therapeutics trading halted, volatility trading pause - TheFly
- 8 days ago - LENZ Therapeutics trading resumes - TheFly
- 8 days ago - Lenz Therapeutics price target raised to $31 from $29 at BofA - TheFly
- 8 days ago - Lenz Therapeutics price target lowered to $38 from $48 at H.C. Wainwright - TheFly
- 8 days ago - Lenz Therapeutics downgraded to Neutral from Overweight at Piper Sandler - TheFly
- 8 days ago - LENZ Therapeutics Q1 Earnings Call Highlights - MarketBeat
- 8 days ago - Lenz Therapeutics reports Q1 EPS ($1.32), consensus ($1.07) - TheFly